Jones Financial Companies Lllp Boosts Stock Holdings in Smith & Nephew plc (NYSE:SNN)

Jones Financial Companies Lllp grew its position in shares of Smith & Nephew plc (NYSE:SNN) by 18.2% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 11,696 shares of the medical equipment provider’s stock after acquiring an additional 1,797 shares during the quarter. Jones Financial Companies Lllp’s holdings in Smith & Nephew were worth $287,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds have also recently bought and sold shares of SNN. US Bancorp DE boosted its holdings in shares of Smith & Nephew by 19.2% in the 3rd quarter. US Bancorp DE now owns 11,167 shares of the medical equipment provider’s stock worth $348,000 after buying an additional 1,802 shares during the last quarter. Oppenheimer Asset Management Inc. boosted its holdings in shares of Smith & Nephew by 5.6% in the 3rd quarter. Oppenheimer Asset Management Inc. now owns 17,218 shares of the medical equipment provider’s stock worth $536,000 after buying an additional 920 shares during the last quarter. Pathstone Holdings LLC boosted its holdings in shares of Smith & Nephew by 14.8% in the 3rd quarter. Pathstone Holdings LLC now owns 48,903 shares of the medical equipment provider’s stock worth $1,523,000 after buying an additional 6,317 shares during the last quarter. Charles Schwab Investment Management Inc. boosted its holdings in shares of Smith & Nephew by 29.3% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 27,199 shares of the medical equipment provider’s stock worth $847,000 after buying an additional 6,164 shares during the last quarter. Finally, Citigroup Inc. boosted its holdings in shares of Smith & Nephew by 18.5% in the 3rd quarter. Citigroup Inc. now owns 119,215 shares of the medical equipment provider’s stock worth $3,712,000 after buying an additional 18,630 shares during the last quarter. 25.64% of the stock is owned by hedge funds and other institutional investors.

Smith & Nephew Stock Down 3.4 %

SNN stock opened at $28.84 on Thursday. The company has a current ratio of 2.51, a quick ratio of 1.11 and a debt-to-equity ratio of 0.63. The company’s 50 day moving average is $26.19 and its 200 day moving average is $27.19. The stock has a market cap of $12.61 billion, a price-to-earnings ratio of 13.35, a price-to-earnings-growth ratio of 1.26 and a beta of 0.83. Smith & Nephew plc has a 1-year low of $23.65 and a 1-year high of $31.72.

Smith & Nephew Increases Dividend

The business also recently disclosed a semi-annual dividend, which will be paid on Wednesday, May 28th. Investors of record on Friday, March 28th will be given a $0.447 dividend. This represents a dividend yield of 2.5%. This is a boost from Smith & Nephew’s previous semi-annual dividend of $0.29. The ex-dividend date of this dividend is Friday, March 28th. Smith & Nephew’s dividend payout ratio is 41.20%.

Wall Street Analyst Weigh In

Several research firms have commented on SNN. Canaccord Genuity Group reaffirmed a “hold” rating and set a $27.00 price objective on shares of Smith & Nephew in a report on Wednesday, February 26th. StockNews.com raised shares of Smith & Nephew from a “buy” rating to a “strong-buy” rating in a report on Wednesday, February 26th. Finally, UBS Group cut Smith & Nephew from a “buy” rating to a “neutral” rating in a research report on Wednesday. Four investment analysts have rated the stock with a hold rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus target price of $27.00.

Smith & Nephew Company Profile

Smith & Nephew plc engages in the development, manufacture, marketing, and sale of medical devices. It operates through the following segments: Orthopaedics, Sports Medicine and ENT, and Advanced Wound Management. The Orthopaedics and Sports Medicine and ENT segment consists of the following businesses: knee implants, hip implants, other reconstruction, trauma, sports medicine joint repair, arthroscopic enabling technologies, and ENT.